tylosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, produced by Streptomyces strains | 5642 | 1401-69-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Macrolide antibiotic obtained from cultures of Streptomyces fradiae. The drug is effective against many microorganisms in animals but not in humans
|
Drug dosage:
None
ADMET properties:
None
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:50904 | alergeno |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| MeSH PA | D000890 | Anti-Infective Agents |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Bovine respiratory complex associated with Pasteurella multocida | Indication |
| Cattle | Necrotic pododermatitis (foot rot) caused by Fusobacterium necrophorum | Indication |
| Cattle | Metritis caused by Arcanobacterium pyogenes | Indication |
| Cattle | To reduce incidence of liver abscesses associated with Fusobacterium necrophorum | Indication |
| Cattle | Bovine respiratory complex associated with Arcanobacterium pyogenes | Indication |
| Cattle | Calf diphtheria caused by Fusobacterium necrophorum | Indication |
| Cattle | To reduce incidence of liver abscesses associated with Arcanobacterium pyogenes | Indication |
| Chickens | To control mortality caused by necrotic enteritis (NE) associated with Clostridium perfringens | Indication |
| Chickens | Air sacculitis (air-sac disease chronic respiratory disease) caused by Mycoplasma gallisepticum | Indication |
| Chickens | CRD associated with Mycoplasma gallisepticum | Indication |
| Chickens | CRD associated with Mycoplasma synoviae | Indication |
| Honey Bees | To control American Foulbrood (Paenibacillus larvae) | Indication |
| Swine | To treat swine arthritis caused by Mycoplasma hyosynoviae | Indication |
| Swine | Swine pneumonia caused by Pasteurella spp | Indication |
| Swine | Swine erysipelas caused by rhusiopathiae | Indication |
| Swine | Swine dysentery associated with Treponema hyodysenteriae | Indication |
| Swine | Swine dysentery associated with B hyodysenteriae | Indication |
| Swine | Atrophic rhinitis | Indication |
| Swine | Proliferative enteropathies (PPE, ileitis) associated with L intracellularis | Indication |
| Turkeys | Infectious sinusitis associated with Mycoplasma gallisepticum | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Tylan 10, Tylan 40, Tylan 100, Tylan 100 CAL | Elanco US Inc. | 1 |
| Tylan 200 Injection, Tylan 50 Injection | Elanco US Inc. | 1 |
| Tylan Soluble | Elanco US Inc. | 1 |
| Tylan 5 Sulfa-G, Tylan 10 Sulfa-G, Tylan 20 Sulfa-G, Tylan 40 Sulfa-G | Elanco US Inc. | 2 |
| Tylan 40 | Zoetis Inc. | 1 |
| Tylan 10 Sulfa-G, Tylan 40 Sulfa-G | Zoetis Inc. | 2 |
| TYLAN 20, TYLAN 40 | Phibro Animal Health Corp. | 1 |
| Rumensin and Tylan | Elanco US Inc. | 2 |
| Tylan and Banminth | Phibro Animal Health Corp. | 2 |
| Component E-C with Tylan, Component E-S with Tylan | Elanco US Inc. | 3 |
| Component E-H with Tylan | Elanco US Inc. | 3 |
| MGA and Rumensin and Tylan | Zoetis Inc. | 3 |
| Tylosin Injection | Huvepharma EOOD | 1 |
| MGA and Bovatec and Tylan | Zoetis Inc. | 3 |
| MGA and Tylan | Zoetis Inc. | 2 |
| MGA and Tylan | Zoetis Inc. | 2 |
| Deccox and Rumensin and Tylan | Zoetis Inc. | 3 |
| Paylean/Tylan | Elanco US Inc. | 2 |
| Optaflexx and Rumensin and Tylan | Elanco US Inc. | 3 |
| Optaflexx and Rumensin and Tylanand MGA | Elanco US Inc. | 4 |
| Zilmax and Rumensin and Tylan | Intervet Inc. | 3 |
| Zilmax and Rumensin and Tylan and MGA | Intervet Inc. | 4 |
| Experior and Rumensin and Tylan | Elanco US Inc. | 3 |
| Component TE-G, Component TE-G with Tylan, Component TE-ID with Tylan, Component TE-IS, Component TE-IS with Tylan, Component TE-S, Component TE-S with Tylan | Elanco US Inc. | 3 |
| Component T-H with Tylan, Component T-S with Tylan | Elanco US Inc. | 2 |
| Component TE-200 with Tylan, Component TE-H with Tylan, Component TE-IH with Tylan | Elanco US Inc. | 3 |
| HeifermaX 500 / Rumensin / Tylan | Elanco US Inc. | 3 |
| Heifermax / Optaflexx / Rumensin / Tylan | Elanco US Inc. | 4 |
| Heifermax 500 Liquid Premix and Tylan | Elanco US Inc. | 2 |
| HeifermaX 500 plus Bovatec and Tylan | Elanco US Inc. | 3 |
| BiloVet | Bimeda Animal Health Limited | 1 |
| Tylovet Soluble | Huvepharma EOOD | 1 |
| Heifermax 500/Zilmax/Rumensin/Tylan | Elanco US Inc. | 4 |
| Tylovet 40, Tylovet 100 | Huvepharma EOOD | 1 |
| BiloVet | Bimeda Animal Health Limited | 1 |
| Paylean plus Tylovet | Huvepharma EOOD | 2 |
| Rumensin plus Tylovet 100 | Huvepharma EOOD | 2 |
| MGA plus Tylovet 100 | Huvepharma EOOD | 2 |
| Deccox, Rumensin, and Tylovet 100 | Huvepharma EOOD | 3 |
| MGA, Rumensin and Tylovet 100 | Huvepharma EOOD | 3 |
| MGA/ Bovatec/ Tylovet 100 | Huvepharma EOOD | 3 |
| Zilmax/Rumensin/Tylovet 100/MGA | Huvepharma EOOD | 4 |
| Zilmax/Rumensin/Tylovet 100 | Huvepharma EOOD | 3 |
| Engain plus Tylan | Zoetis Inc. | 2 |
| Actogain 45/Rumensin/Tylan | Zoetis Inc. | 3 |
| Actogain 45/Rumensin/Tylan/MGA | Zoetis Inc. | 4 |
| Optaflexx 45/Rumensin/Tylovet 100 | Huvepharma EOOD | 3 |
| Optaflexx 45/Rumensin/Tylovet 100/MGA | Huvepharma EOOD | 4 |
| Actogain 45/Rumensin/Tylovet 100/MGA | Zoetis Inc. | 4 |
| Engain plus Tylovet 100 | Zoetis Inc. | 2 |
| Actogain 45/Rumensin/Tylovet 100 | Zoetis Inc. | 3 |
| Monovet and Tylovet | Huvepharma EOOD | 2 |
| Monovet and Tylan | Huvepharma EOOD | 2 |
| Optaflexxand Monovet and Tylovet | Huvepharma EOOD | 3 |
| Actogain and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Optaflexxand Monovet and Tylan | Huvepharma EOOD | 3 |
| Actogain and Monovet and Tylan | Huvepharma EOOD | 3 |
| Optaflexx and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| Actogain and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| Optaflexx and Monovet and Tylan and MGA | Huvepharma EOOD | 4 |
| Actogain and Monovet and Tylan and MGA | Huvepharma EOOD | 4 |
| Deccox and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Deccox and Monovet and Tylan | Huvepharma EOOD | 3 |
| MGA and Monovet and Tylovet | Huvepharma EOOD | 3 |
| MGA and Monovet and Tylan | Huvepharma EOOD | 3 |
| Optigrid and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Optigrid and Monovet and Tylovet and MGA | Huvepharma EOOD | 4 |
| CycleGuard and Monovet and Tylovet | Huvepharma EOOD | 3 |
| Optigrid and Monovet and Tylovet and CycleGuard | Huvepharma EOOD | 4 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| CHEBI:17658 | CHEBI |
| TYK | PDB_CHEM_ID |
| CHEMBL42743 | ChEMBL_ID |
| DB11475 | DRUGBANK_ID |
| D015645 | MESH_DESCRIPTOR_UI |
| C0041441 | UMLSCUI |
| 2109 | INN_ID |
| 373553006 | SNOMEDCT_US |
| 96020006 | SNOMEDCT_US |
| 96021005 | SNOMEDCT_US |
| 96022003 | SNOMEDCT_US |
| 1405-53-4 | SECONDARY_CAS_RN |
| 74610-55-2 | SECONDARY_CAS_RN |
| D02490 | KEGG_DRUG |
| 5280440 | PUBCHEM_CID |
| 1363719 | RXNORM |
| NOCODE | MMSL |
| YEF4JXN031 | UNII |
Pharmaceutical products:
None